ERBB2 and non-small cell lung carcinoma: In a randomised phase II trial comparing neratinib alone or in combination with temsirolimus in HER2-mutant advanced NSCLC, combination therapy achieved an ORR of 19% vs. 0% with neratinib alone [33].